Composition for preventing or treating ischemic stroke comprising taurodeoxycholic acid

TDCA composition provides a safe and effective neuroprotective treatment for ischemic stroke by reducing cerebral infarction and neuronal damage, addressing limitations of current therapies with improved safety and applicability.

WO2026240609A1PCT designated stage Publication Date: 2026-11-19SHAPERON INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/096945
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current treatments for ischemic stroke have limited efficacy and safety concerns, particularly due to the high risk of hemorrhagic complications and narrow time window for intervention, necessitating the development of safe and effective neuroprotective drugs.

Method used

A pharmaceutical composition containing taurodeoxycholic acid (TDCA) is administered intravenously or intraperitoneally, demonstrating dose-dependent neuroprotective effects by reducing cerebral infarction and neuronal destruction in animal models, complementing existing thrombolytic therapies.

Benefits of technology

TDCA significantly reduces cerebral infarction volume and neuronal damage, offering a safer and more effective treatment option for ischemic stroke with a wider therapeutic window and lower risk of side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026096945_19112026_PF_FP_ABST
    Figure KR2026096945_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating stroke, the pharmaceutical composition comprising taurodeoxycholic acid (TDCA). It was confirmed that the extent of cerebral infarction significantly decreased as a result of applying the composition according to the present invention to an ischemic stroke animal model, which suggests new treatment strategies useful for ischemic stroke. Accordingly, the composition according to the present invention is useful as a therapeutic agent that overcomes the limitations of existing treatments and can be safely applied within a broader therapeutic window.
Need to check novelty before this filing date? Find Prior Art

Description

Composition for the prevention or treatment of ischemic stroke containing taurodeoxycholic acid

[0001] The present invention relates to a pharmaceutical composition for the prevention or treatment of stroke comprising taurodeoxycholic acid (TDCA), and more specifically, to a pharmaceutical composition for the prevention or treatment of stroke, preferably ischemic stroke, comprising taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

[0002]

[0003] Stroke is a disease in which blood vessels supplying blood to the brain become blocked or rupture, causing damage to brain tissue. Depending on the location of the damage, it results in impairments in physical, mental, daily living functions, and social functions, such as motor, sensory, speech, and consciousness disorders. Stroke is classified into hemorrhagic stroke caused by cerebral hemorrhage and ischemic stroke (cerebral infarction) caused by localized ischemia or infarction resulting from a blockage of blood vessels.

[0004] Hemorrhagic stroke occurs when a blood vessel in the brain ruptures and is divided into intracerebral hemorrhage and subarachnoid hemorrhage. Intracerebral hemorrhage occurs when blood accumulates inside the brain as a blood vessel ruptures, most commonly in the basal ganglia or thalamus. Subarachnoid hemorrhage is a condition in which blood accumulates beneath the arachnoid membrane surrounding the brain due to the rupture of an aneurysm (a bulge of blood vessel wall due to weakened walls) or a vulnerable vessel rupturing in an arteriovenous malformation. It is characterized by severe headaches and vomiting, and while most cases do not involve hemiplegia, it can progress to quadriplegia and severe cognitive impairment.

[0005] Ischemic stroke is a disease in which brain tissue damage is caused by insufficient blood supply resulting from the partial or complete blockage of cerebral blood flow (cerebral vascular occlusion). Major causes of cerebral vascular occlusion include blood clots in cerebral blood vessels caused by factors such as arteriosclerosis, and cerebral embolism, where blood clots originating from the heart or surrounding organs break off and block cerebral vessels. Ischemic stroke can be classified into total ischemia and partial ischemia depending on the degree of circulatory impairment. In cases of total ischemia, blood supply to a localized area is completely cut off, causing a portion of brain tissue to die and resulting in permanent disability due to the cerebral infarction. In cases of partial ischemia, however, rapidly restoring cerebral blood flow can prevent the death of brain cells and allow for the recovery of function. Generally, the nature of the disability is determined by the function of the damaged brain area. Various functional impairments—such as hemiplegia, aphasia, hemisensory abnormalities, cognitive decline, visual perception disorders, swallowing difficulties, and urinary disorders—make it difficult to perform daily activities independently or significantly reduce efficiency, thereby lowering the quality of life.

[0006] Stroke is one of the leading causes of death and severe disability worldwide, resulting in an annual incidence of millions and a massive social and economic burden. In the case of cerebrovascular disease, there are no alternative treatments other than those for blood flow reperfusion during the acute phase and subsequent rehabilitation; furthermore, the duration during which rehabilitation can be expected to be effective is limited. In the case of cerebral infarction, where a cerebral blood vessel is blocked, a method involving the immediate administration of thrombolytic agents to dissolve the blood clot blocking the vessel and restore blood flow to the cerebral blood vessels is used. While the intravenous administration of a thrombolytic agent (Tissue-type Plasminogen Activator, t-PA) within three hours of the onset of cerebral infarction has the advantage of convenience, it can act on areas other than the blood clot within the cerebral blood vessels, potentially inducing bleeding; it is difficult to verify the effect immediately; and patients rarely arrive at the hospital within three hours. The method of directly identifying blocked cerebral blood vessels via angiography, inserting a catheter into the site, and administering thrombolytic agents is more effective than the intravenous method, but it is difficult to always perform in all hospitals due to the high time and manpower requirements. These treatment methods have a very limited window for treatment and have limitations in widespread application due to the high risk of serious side effects, such as hemorrhagic complications.

[0007] Accordingly, there has been a persistent need for effective and safe novel therapeutic strategies, particularly for the development of drugs with neuroprotective effects. While some conventional technologies have proposed studies on neuroprotective effects utilizing bile acid derivatives or their pharmacological activity, there is currently a lack of clinically established bile acid-derived therapies for ischemic stroke. For instance, existing studies have demonstrated neuroprotective effects in some animal models, but sufficient safety and efficacy data for clinical application have not been secured. Therefore, there is an urgent need for the development of safe and effective compositions for the treatment of ischemic stroke through novel pharmacological approaches.

[0008]

[0009] Against this technical background, the inventors present an innovative turning point in the field of stroke treatment by providing a novel composition effective for the treatment of stroke, particularly ischemic stroke, and will be able to contribute to improving patient prognosis and reducing the medical burden.

[0010]

[0011] The information described above in the background section is intended solely to enhance understanding of the background of the present invention and may not include information that forms prior art already known to those skilled in the art to which the present invention belongs.

[0012]

[0013] [Prior Art Literature]

[0014] [Patent Literature]

[0015] Korean Registered Patent No. 2204406

[0016] Korean Patent Publication No. 2005-0103185

[0017] U.S. Patent Publication No. 2009 / 0312297

[0018]

[0019] The object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of stroke comprising taurodeoxycholic acid.

[0020] Another objective of the present invention is to provide a method for preventing or treating stroke using taurodeoxycholic acid, the use of taurodeoxycholic acid for the prevention or treatment of stroke, and the use of taurodeoxycholic acid for the manufacture of a drug for the prevention or treatment of stroke.

[0021] Another objective of the present invention is to provide a food composition for preventing or improving stroke containing taurodeoxycholic acid.

[0022]

[0023] To achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of stroke comprising taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

[0024] The present invention also provides a method for preventing or treating stroke, comprising the step of administering taurodeoxycholic acid or a pharmaceutically acceptable salt thereof.

[0025] The present invention also provides the use of taurodeoxycholic acid or a pharmaceutically acceptable salt thereof for the prevention or treatment of stroke.

[0026] The present invention also provides the use of taurodeoxycholic acid or a pharmaceutically acceptable salt thereof for the manufacture of a drug for the prevention or treatment of stroke.

[0027] The present invention also provides a food composition for preventing or improving stroke comprising taurodeoxycholic acid or a salt thereof as an active ingredient.

[0028]

[0029] As a result of applying the composition according to the present invention to an animal model of ischemic stroke, it was confirmed that neuronal destruction and the extent of cerebral infarction were significantly reduced, which proposes a new therapeutic strategy useful for ischemic stroke. Accordingly, it is useful as a therapeutic agent that overcomes the limitations of existing treatments and can be safely applied over a wider time window.

[0030]

[0031] Figure 1 shows the dose-dependent neuroprotective effects following intravenous administration of a composition (NuStrokin) containing taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an active ingredient in a rat model of ischemic stroke induced by middle cerebral artery occlusion (MCAO). After inducing transient MCAO in adult rats, vehicle (PBS) or NuStrokin was intravenously administered at doses of 0.03, 0.125, 0.25, 0.5, 1, 2, or 4 mg / kg, while only vehicle was administered to the sham surgery group (MCAO-). Figure 1A shows a representative 2,3,5-triphenyltetrazolium chloride (TTC) stained image of coronal brain sections collected 72 hours after MCAO induction, where viable tissue is indicated in red and infarcted areas in light colors. Figure 1B shows the results of calculating the cerebral infarction volume of the ipsilateral cerebral hemisphere as a percentage relative to the contralateral cerebral hemisphere. Data were expressed as mean ± SEM, and statistical significance was tested using Student's t-test against the MCAO + vehicle group.

[0032] Figure 2 shows the effect of intravenous or intraperitoneal administration of NuStrokin on reducing cerebral infarction volume in a rat MCAO model. After inducing transient MCAO in adult rats, the vehicle (PBS) or NuStrokin was administered intravenously (IV, 1 mg / kg) or intraperitoneally (IP, 1, 2, or 4 mg / kg), while only the vehicle was administered to the sham surgery group. Figure 2A shows representative TTC stained images of coronal brain sections collected 72 hours after MCAO induction, where viable tissue is indicated in red and infarcted areas in light shades. Figure 2B shows the results of calculating the cerebral infarction volume of the ipsilateral cerebral hemisphere as a percentage relative to the contralateral cerebral hemisphere. Data are expressed as mean ± SEM, and statistical significance was tested using Student's t-test against the MCAO + vehicle group.

[0033]

[0034] Specific details for implementing the invention

[0035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by a skilled expert in the art to which this invention pertains. In general, the nomenclature used herein is well known and commonly used in the art.

[0036]

[0037] In one embodiment of the present invention, a composition (NuStrokin) containing TDCA as an active ingredient was administered intravenously and intraperitoneally to an MCAO animal model. As a result, the TDCA administration group showed a significantly reduced cerebral infarction area compared to the PBS administration control group. Visualization of the cerebral infarction area after 72 hours using TTC staining confirmed that all TDCA administration groups (G3–G9) showed a statistically significant reduction compared to the control group (G2). Furthermore, the effect of reducing the cerebral infarction area became more pronounced as the TDCA administration concentration increased, and the effect gradually increased as it was administered from a low concentration (G3: 0.03 mpk) to a high concentration (G9: 4 mpk). This demonstrates that the composition of the present invention can alleviate brain damage caused by ischemic stroke and suggests that therapeutic efficacy can be maximized by setting the optimal therapeutic dose based on the dose-dependent effect.

[0038] Meanwhile, TDCA is a bile acid-derived substance whose safety has already been verified, and a relatively safe drug profile can be expected for human application. In particular, the composition of the present invention has a lower risk of side effects, such as hemorrhagic complications, compared to existing treatments, thereby increasing the potential for clinical development as a treatment for ischemic stroke. Furthermore, it has high clinical utility as it can be administered via various routes in addition to intravenous injection. Moreover, since TDCA prevents neuronal destruction caused by ischemic damage and reduces the extent of cerebral infarction through a neuroprotective mechanism that inhibits cell death pathways, it can complement the therapeutic effects when used in combination with existing thrombolytic therapy.

[0039] In summary, the composition according to the present invention is a safe therapeutic agent with proven therapeutic effects that enhances therapeutic efficiency through various administration routes and provides a new alternative for the treatment of ischemic stroke by complementing existing therapeutic agents when used in combination.

[0040]

[0041] Accordingly, in one aspect, the present invention relates to a pharmaceutical composition for the prevention or treatment of stroke comprising taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

[0042] In another aspect, the present invention relates to a method for preventing or treating stroke comprising the step of administering taurodeoxycholic acid or a pharmaceutically acceptable salt thereof.

[0043] In another aspect, the present invention relates to the use of taurodeoxycholic acid or a pharmaceutically acceptable salt thereof for the prevention or treatment of stroke.

[0044] In another aspect, the present invention relates to the use of taurodeoxycholic acid or a pharmaceutically acceptable salt thereof for the manufacture of a drug for the prevention or treatment of stroke.

[0045] The term “prevention” as used in the present invention refers to any act of preventing the onset of a stroke or delaying its progression through the administration of the above-mentioned composition. Furthermore, the term “treatment” as used in the present invention refers to any act of improving, alleviating, or completely curing the symptoms of a stroke through the administration of the above-mentioned composition.

[0046]

[0047] In the present invention, the taurodeoxycholic acid (TDCA) is a type of bile acid, in the form of taurine-conjugated deoxycholic acid, and has a chemical structure represented by [Chemical Formula 1] below, and more specifically, has a chemical structure represented by [Chemical Formula 2] below.

[0048] [Chemical Formula 1]

[0049]

[0050] [Chemical Formula 2]

[0051]

[0052] In the present invention, the taurodeoxycholic acid may be used as it is isolated from animals, such as humans, cattle, pigs, sheep, dogs, goats, or rabbits, is commercially available, or is synthesized.

[0053]

[0054] In the present invention, the composition comprises taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient, and an acid addition salt formed by a pharmaceutically acceptable free acid is useful as the pharmaceutically acceptable salt. Inorganic acids and organic acids may be used as free acids; hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, etc. may be used as inorganic acids, and citric acid, acetic acid, lactic acid, maleic acid, fumaric acid, gluconic acid, methanesulfonic acid, glyconic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, emvonic acid, glutamic acid, aspartic acid, etc. may be used as organic acids. Preferably, the salt may be characterized as being one or more salts selected from the group consisting of hydrochloride, sulfate, phosphate, mesylate, malate, maleate, mesylate, besylate, hydrogen sulfate, oxalate, fumarate, tartarate, citrate, succinate, and acetate, but is not limited thereto, and is designed to function stably in the body.

[0055] The taurodeoxycholic acid according to the present invention comprises not only pharmaceutically acceptable salts but also all salts, stereoisomers, hydrates, and solvates that can be prepared by conventional methods.

[0056]

[0057] In the present invention, the stroke may be characterized as being an ischemic stroke or a hemorrhagic stroke.

[0058] Preferably, the stroke may be characterized as an ischemic stroke, but is not limited thereto.

[0059]

[0060] In the present invention, the taurodeoxycholic acid or a pharmaceutically acceptable salt thereof may be characterized by being included in an amount of 0.03 mg / ml to 10 mg / ml, but is not limited thereto. Preferably, it may be characterized by being included in an amount of 0.05 mg / ml to 8 mg / ml, more preferably 0.1 mg / ml to 6 mg / ml, and most preferably 0.1 mg / ml to 4 mg / ml, but is not limited thereto.

[0061]

[0062] In the present invention, the composition may additionally comprise a suitable pharmaceutically acceptable carrier, excipient, stabilizer, solvent, or diluent according to conventional methods. The term “pharmaceutically acceptable” means a substance that is physiologically acceptable and, when administered to humans, does not typically cause allergic reactions such as gastrointestinal disorders or dizziness, or similar reactions. Carriers, excipients, and diluents that may be included in a composition containing a compound include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0063] When formulating the composition of the present invention, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules, and these solid dosage forms are prepared by mixing at least one excipient with the above compounds, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid dosage forms for oral administration include suspensions, liquid formulations, emulsions, and syrups, and may include various excipients, for example, wetting agents, sweeteners, flavoring agents, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As bases for suppositories, Witepsol, Macrogol, Tween 60, cocoa paste, laurin paste, glycerogelatin, etc. may be used.

[0064] The composition containing taurodeoxycholic acid of the present invention may have a formulation selected from the group consisting of injectables, liquid formulations, tablets, capsules, troches, powders, pills, granules, suspensions, oral liquids, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, lyophilized suppositories, and vaginal tablets according to conventional methods, but is not limited thereto, and can be formulated into an appropriate formulation as needed.

[0065]

[0066] In the present invention, the term "administration" means providing a specific substance to a patient by any suitable method, and the route of administration of the composition of the present invention may be oral or parenteral (e.g., intravenously, subcutaneously, intraperitoneally, or topically) through any general route capable of reaching the target tissue. Additionally, the composition may be administered by any device capable of delivering the active substance to target cells.

[0067] The composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including the type and severity of the patient's disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects by taking all of the above-mentioned factors into account, and this can be easily determined by a person skilled in the art.

[0068] Specifically, the effective amount of the compound according to the present invention may vary depending on the patient's age, gender, and weight, and may be administered daily or every other day, or divided into 1 to 3 doses per day. However, since the dosage may be increased or decreased depending on the route of administration, severity, gender, weight, age, etc., the above dosage does not limit the scope of the present invention in any way.

[0069]

[0070] In another aspect, the present invention relates to a food composition for preventing or improving stroke comprising taurodeoxycholic acid or a food-grade acceptable salt thereof as an active ingredient.

[0071] The term “improvement” in the present invention refers to any act that at least reduces parameters related to the state of a disease being treated by the administration (or application) of the above composition, such as the degree of symptoms.

[0072] In the present invention, the terms food composition, health functional food composition, or health functional food are used interchangeably.

[0073] The food composition of the present invention can be used in various ways, such as in pharmaceuticals, foods, and beverages for preventing oxidation. The health functional food of the present invention includes, for example, various types of food, candy, chocolate, beverages, gum, tea, vitamin complexes, health supplements, etc., and can be used in the form of powder, granules, tablets, capsules, or beverages.

[0074] The above pharmaceutical composition of the present invention may be added to food or beverages for the purpose of preventing or improving stroke.

[0075] The health beverage composition of the present invention has no particular restrictions on the liquid components other than containing the extract as an essential component in the indicated proportion, and may contain various flavoring agents or natural carbohydrates as additional components, as in conventional beverages. Examples of the natural carbohydrates mentioned above include monosaccharides, disaccharides such as glucose and fructose, polysaccharides such as maltose and sucrose, conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) may be advantageously used. The proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g, per 100 ml of the composition of the present invention.

[0076] The composition of the present invention may contain various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the compositions of the present invention may contain fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used independently or in combination. Although the proportion of these additives is not particularly important, it is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

[0077]

[0078] The present invention will be described in more detail below through examples. These examples are intended solely to illustrate the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.

[0079]

[0080] Example 1: Preparation of an ischemic stroke animal model and administration of taurodeoxycholic acid (TDCA)

[0081] [Preparation of Experimental Animals]:

[0082] The animals used to create a model of cerebral ischemia caused by middle cerebral artery occlusion were 8-week-old male Sprague-Dawley rats (body weight 270–290 g) purchased from SAMTAKO (Osan-si, Korea). During the experiment, feed and water were provided to the animals without restriction, and the experimental environment was maintained at a temperature of 23±3℃, a relative humidity of 50±10%, and a 12-hour light-dark cycle. All experiments were conducted in accordance with the standard guidelines of the Laboratory Animal Resource Management Center at Seoul National University and were approved by the Animal Ethics Committee.

[0083] [Middle Cerebral Artery Occlusion (MCAO)]:

[0084] Middle cerebral artery occlusion surgery was performed using a modified method of Longa et al. (1989) (BS Aspey et al., 1998). First, anesthesia was induced with isoflurane, and anesthesia was maintained using oxygen and isoflurane. After fixing the rats in the abdominal position, an incision was made along the midline of the neck to expose the left common carotid artery (CCA), internal carotid artery (ICA), and external carotid artery (ECA). The upper part of the ECA and the lower part of the CCA were completely ligated with sutures to occlude them, while the ICA portion was loosely ligated with sutures and then closed with a clip. A hole was made in the center of the CCA, and a silicone-coated suture (Silicone Coated MCAO Monofilament Suture (USA, RWD)) was inserted. It was then advanced 18 mm toward the ICA and positioned at the origin of the middle cerebral artery. Subsequently, it was ligated and fixed together with the vessel. One hour after middle cerebral artery occlusion, the suture was removed to induce reperfusion.

[0085] [Administration of Taurodeoxycholic Acid (TDCA)]

[0086] After 24 hours had elapsed following reperfusion induction, rats were placed in restraint cages, and intravenous or intraperitoneal administration was performed. For intravenous administration, a catheter was first inserted into the tail vein. A 10 mL syringe was connected to the catheter and then connected to an infusion pump to infuse taurodeoxycholic acid (TDCA) at a rate of 3 mL / hr. Intravenous administration was performed once (single dose) over 20 minutes at concentrations ranging from 0.03 to 4 mpk for each administration group. After 72 hours, the brains were excised and TTC staining was performed.

[0087] For intraperitoneal administration, each administration group was injected once a day for 3 days at concentrations of 1, 2, and 4 mpk. After 72 hours, the brain was excised and TTC staining was performed.

[0088] [TTC Staining]

[0089] First, the brain was isolated and placed in a trough filled with cold PBS at 4°C for 10 minutes to prepare the brain slices. Subsequently, the brain slices were stored in PBS at room temperature for less than 3 minutes before being transferred to TTC culture medium, and then incubated in TTC medium at 37°C for 30 minutes. Next, after washing with PBS for 3–5 minutes, the stained slices were fixed in a buffered formaldehyde solution for 30 minutes to 24 hours. Infarct volume was quantified using standard image analysis software (ImageJ), and the infarct brain volume was analyzed as a percentage of the total brain size.

[0090]

[0091] The animals were divided into 6–9 groups as shown in Tables 1 and 2 below for the experiment:

[0092]

[0093]

[0094] Example 2: Confirmation of changes in cerebral infarction extent following TDCA administration in an MCAO animal model

[0095] Figure 1 shows the results of measuring the extent of cerebral infarction 72 hours after MCAO induction by TTC (Triphenyl tetrazolium chloride) staining for the animal groups of Example 1 (Table 1, G1~G9).

[0096]

[0097] Example 3: Confirmation of changes in cerebral infarction extent following TDCA administration in an MCAO animal model

[0098] Figure 2 shows the results of measuring the extent of cerebral infarction 72 hours after MCAO induction by TTC (Triphenyl tetrazolium chloride) staining for the animal groups of Example 1 (Table 2, G1~G6).

[0099]

[0100] As shown in Figures 1 and 2, the TDCA administration groups showed significantly reduced cerebral infarction volume compared to the PBS administration control group (MCAO + PBS), which suggests that the composition of the present invention can be usefully applied to ischemic stroke.

[0101]

[0102] Foregoing, specific parts of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.

Claims

1. A pharmaceutical composition for the prevention or treatment of stroke comprising taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

2. A pharmaceutical composition according to claim 1, characterized in that the taurodeoxycholic acid is a compound represented by the following chemical formula 2: [Chemical Formula 2] 3. A pharmaceutical composition according to claim 1, wherein the salt is one or more salts selected from the group consisting of hydrochloride, sulfate, phosphate, mesylate, malate, maleate, mesylate, besylate, hydrogen sulfate, oxalate, fumarate, tartarate, citrate, succinate, and acetate.

4. A pharmaceutical composition according to claim 1, characterized in that the stroke is an ischemic stroke or a hemorrhagic stroke.

5. A pharmaceutical composition according to claim 1, characterized in that the taurodeoxycholic acid or a pharmaceutically acceptable salt thereof is contained in an amount of 0.03 mg / ml to 10 mg / ml.

6. A pharmaceutical composition according to claim 1, characterized by additionally comprising one or more pharmaceutically acceptable carriers.

7. A food composition for preventing or improving stroke comprising taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient.